FDA Grants Fast Track Designation to Yutrepia for Raynaud's Phenomenon in Systemic Sclerosis
核心洞察
The FDA has granted fast track designation to Yutrepia (搜索), an inhalable dry-powder treprostinil, for Raynaud's phenomenon (搜索) associated with systemic sclerosis (搜索).
The phase 2a RE-WARM trial will assess safety and pharmacodynamics of Yutrepia (搜索) in about 75 U.S. adults across 30 sites, starting in October.
Yutrepia (搜索) is already approved for pulmonary arterial hypertension (搜索) and pulmonary hypertension associated with interstitial lung disease (搜索).
The FDA has granted fast track designation to Yutrepia (搜索) for the treatment of Raynaud's phenomenon (搜索) associated with systemic sclerosis (搜索) (SSc), according to a press release from the manufacturer. Yutrepia (Liquidia (搜索)) is an inhalable dry-powder formulation of treprostinil delivered through a palm-sized device. The drug is currently approved for pulmonary arterial hypertension (搜索) and for pulmonary hypertension associated with interstitial lung disease (搜索).
The designation supports the phase 2a RE-WARM trial, which will evaluate the safety and pharmacodynamics of Yutrepia (搜索) in approximately 75 U.S. adults with SSc-associated Raynaud's phenomenon (搜索) across 30 sites. The study is expected to begin in October. Fast track status makes sponsors eligible for more frequent interactions with the FDA during clinical development.
Raynaud's phenomenon (搜索) affects roughly 95% of patients with systemic sclerosis (搜索), and recurrent reductions in blood flow can cause pain, loss of hand function, digital ulcers, infection and, in severe cases, irreversible tissue damage including gangrene and amputations. Existing options remain limited, are frequently used off-label, and may not provide adequate benefit or may cause systemic side effects.